
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
San Francisco - According to an analysis of data from more than 700 patients, a new nonsteroid treatment for atopic dermatitis is a safe, effective, and cost-effective alternative to conventional therapy for the chronic, relapsing inflammatory skin disease that primarily affects infants and children.